DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



PK and Safety Study of XARTEMIS� XR (7.5 mg Oxycodone HCl/325 mg APAP) in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain

Information source: Mallinckrodt
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Acute Pain

Intervention: XARTEMIS XR (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Mallinckrodt

Overall contact:
Jeannie Montgomery, Phone: 314-654-3528, Email: Jeannie.Montgomery@mallinckrodt.com

Summary

Phase 4, multicenter, open-label, multiple-dose study of the pharmacokinetics (PK) and safety of XARTEMIS XR in postsurgical adolescent subjects aged 12 to 17 years with moderate to severe acute pain. The study will assess the safety of administering multiple doses of XARTEMIS XR in this population.

Clinical Details

Official title: A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of XARTEMIS XR (7.5 Oxycodone Hydrochloride/325 mg Acetaminophen) in Postsurgical Adolescent Subjects (Ages 12 to 17) With Moderate to Severe Acute Pain

Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Time to reach steady state

Area under the curve

Peak exposure

Half-life

Time to peak exposure

Eligibility

Minimum age: 12 Years. Maximum age: 17 Years. Gender(s): Both.

Criteria:

Inclusion criteria: 1. Male or nonpregnant, nonlactating females between 12 and 17 years of age. 2. Minimum weight of 100 pounds (45 kg); body mass index (BMI) >5% and <95% for their age. 3. Moderate or severe acute pain (as determined from the Numerical Pain Rating scale [NPRS]; must have a level of 4 or more) after surgical procedure requiring hospitalization. 4. If, of child-bearing/reproductive potential, must abstain from unprotected sexual activity during study and 2 weeks after study exit. 5. Females of childbearing potential must have negative pregnancy test. 6. Subject's legally authorized representative (eg, parent, legal guardian) must sign a parental permission/informed consent and subject must sign an assent. 7. Subject and subject's parent/legal guardian must be able to read, understand, and follow study procedures and requirements and communicate meaningfully in English. Exclusion criteria: 1. Subject is from a vulnerable population (including mentally disabled children), other than a pediatric population. 2. Subject requires surgery that could influence the study outcome. 3. Abnormal electrocardiogram (ECG). 4. Screening pulse oximetry reading of <95% while awake. 5. Has presence of human immunodeficiency virus (HIV) or indications of hepatitis A, B or C. 6. Lab values greater than 2 times the upper limit of normal. 7. History of renal disease or bleeding or clotting disorders or conditions. 8. Known or suspected alcoholism, marijuana or illicit drug abuse or misuse within 2 years before screening. 9. Smoked or used nicotine-containing products within 6 months prior to screening. 10. Psychiatric disorders, such as major depression disorder, anxiety disorders, or psychotic disorders within 6 months prior to screening. A history of attention deficit hyperactivity disorder requiring medication is acceptable. 11. Diagnosis of epilepsy or other seizure disorder. 12. Previous cardiothoracic surgery. 13. Conditions which might be specifically contraindicated or require caution while using OC, APAP, and/or ibuprofen. 14. Drug allergy, hypersensitivity, or intolerance including OC, APAP, ibuprofen or excipients, or any opioid drug product. 15. Donated or had significant loss of whole blood (480 mL or more) within 30 days of or plans to donate blood or plasma during the course of the study. 16. Pathologic, iatrogenic or surgical condition that would compromise subject's ability to swallow, absorb, metabolize, or excrete XARTEMIS XR. 17. History of a GI event within 6 months prior to screening. 18. Subject has used any product containing OC or APAP within 48 hours prior to the first dose of XARTEMIS XR. 19. Any other medical condition, abnormal vital sign (blood pressure, pulse rate, respiratory rate), body temperature, pulse oximetry; or any physical examination or ECG finding at screening which would preclude safe participation in a clinical study. 20. Received any investigational product or device within 30 days before screening, or is scheduled to receive an investigational device or another investigational drug during the course of this study.

Locations and Contacts

Jeannie Montgomery, Phone: 314-654-3528, Email: Jeannie.Montgomery@mallinckrodt.com

Duke University Health Systems, Durham, North Carolina 27710, United States; Recruiting
Katherine Sweeney, Phone: 919-681-6221, Email: Katherine.Sweeney@duke.edu
Allison Ross, MD, Principal Investigator
Additional Information

Starting date: June 2015
Last updated: July 23, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017